| Primary |
| Product Used For Unknown Indication |
67.6% |
| Hyperphosphataemia |
18.7% |
| Drug Use For Unknown Indication |
2.6% |
| Hypertension |
2.2% |
| Renal Failure Chronic |
1.7% |
| Chronic Obstructive Pulmonary Disease |
0.9% |
| Renal Disorder |
0.9% |
| Blood Phosphorus Abnormal |
0.7% |
| Anaemia |
0.6% |
| Prophylaxis |
0.5% |
| Diabetes Mellitus |
0.4% |
| Gout |
0.4% |
| Hypothyroidism |
0.4% |
| Vitamin D |
0.4% |
| Anticoagulant Therapy |
0.3% |
| Blood Pressure |
0.3% |
| Hypercholesterolaemia |
0.3% |
| Hyperlipidaemia |
0.3% |
| Hyperparathyroidism Secondary |
0.3% |
| Hyperuricaemia |
0.3% |
|
| Constipation |
37.0% |
| Pruritus |
13.8% |
| Death |
11.3% |
| Diarrhoea |
8.6% |
| Nausea |
5.9% |
| Vomiting |
5.6% |
| Flatulence |
2.3% |
| Abdominal Pain |
1.9% |
| Hospitalisation |
1.9% |
| Rash |
1.7% |
| Cardiac Arrest |
1.2% |
| Intestinal Obstruction |
1.2% |
| Oral Administration Complication |
1.2% |
| Overdose |
1.2% |
| Dyspepsia |
1.0% |
| Abdominal Pain Upper |
0.9% |
| Gastrointestinal Motility Disorder |
0.9% |
| Hyperphosphataemia |
0.9% |
| Malaise |
0.7% |
| Myocardial Infarction |
0.7% |
|
| Secondary |
| Product Used For Unknown Indication |
63.8% |
| Hyperphosphataemia |
11.7% |
| Haemolytic Uraemic Syndrome |
2.8% |
| Hypertension |
2.4% |
| Renal Failure Chronic |
2.4% |
| Blood Phosphorus Abnormal |
2.3% |
| Vitamin D |
2.0% |
| Hyperparathyroidism Secondary |
1.4% |
| Myocardial Ischaemia |
1.4% |
| Drug Use For Unknown Indication |
1.3% |
| Diabetes Mellitus |
1.1% |
| Hypothyroidism |
1.1% |
| Prophylaxis |
1.0% |
| Anaemia |
0.9% |
| Rheumatoid Arthritis |
0.9% |
| Gout |
0.7% |
| Hypercholesterolaemia |
0.7% |
| Liver Transplant |
0.7% |
| Neuropathy Peripheral |
0.7% |
| Antidepressant Therapy |
0.6% |
|
| Diarrhoea |
10.2% |
| Angiogram |
8.2% |
| Cardio-respiratory Arrest |
6.1% |
| Drug Interaction |
6.1% |
| Faeces Discoloured |
6.1% |
| Vertigo |
6.1% |
| Abortion Spontaneous |
4.1% |
| Angioplasty |
4.1% |
| Congestive Cardiomyopathy |
4.1% |
| Death |
4.1% |
| Drug Ineffective |
4.1% |
| Flatulence |
4.1% |
| General Physical Health Deterioration |
4.1% |
| Hospitalisation |
4.1% |
| Lower Limb Fracture |
4.1% |
| Maternal Exposure During Pregnancy |
4.1% |
| Nausea |
4.1% |
| Neutropenia |
4.1% |
| Noninfectious Peritonitis |
4.1% |
| Palpitations |
4.1% |
|
| Concomitant |
| Product Used For Unknown Indication |
56.1% |
| Drug Use For Unknown Indication |
9.9% |
| Nuclear Magnetic Resonance Imaging |
4.5% |
| Hyperparathyroidism Secondary |
4.0% |
| Hypertension |
2.9% |
| Renal Failure Chronic |
2.6% |
| Dialysis |
2.4% |
| Multiple Myeloma |
2.3% |
| Hyperparathyroidism |
2.1% |
| Peritoneal Dialysis |
1.9% |
| Pain |
1.6% |
| Anaemia |
1.4% |
| Hyperphosphataemia |
1.4% |
| Imaging Procedure |
1.2% |
| Angiogram |
1.2% |
| Nuclear Magnetic Resonance Imaging Brain |
1.1% |
| Prophylaxis |
0.9% |
| Nephrogenic Anaemia |
0.9% |
| Diabetes Mellitus |
0.8% |
| Nausea |
0.7% |
|
| Death |
12.2% |
| Vomiting |
10.6% |
| Pneumonia |
7.4% |
| Therapeutic Response Decreased |
5.8% |
| Weight Decreased |
5.8% |
| Haemoglobin Decreased |
5.3% |
| Peritonitis Bacterial |
5.3% |
| Swelling |
5.3% |
| Pruritus |
4.2% |
| Sudden Death |
4.2% |
| Anaemia |
3.7% |
| Drug Ineffective |
3.7% |
| Nephrogenic Systemic Fibrosis |
3.7% |
| Renal Failure Chronic |
3.7% |
| Blood Parathyroid Hormone Decreased |
3.2% |
| Dyspnoea |
3.2% |
| Fall |
3.2% |
| Hypertension |
3.2% |
| Nausea |
3.2% |
| Renal Failure |
3.2% |
|
| Interacting |
| Hiv Infection |
42.9% |
| Hypertension |
28.6% |
| Hyperphosphataemia |
21.4% |
| Renal Failure |
7.1% |
|
| Drug Interaction |
50.0% |
| Pancreatitis Acute |
50.0% |
|
